Researchers have discovered another potential drug that could help treat COVID-19 by preventing serious neo crown complications,media BGR reported. Aprotinin is an antiviral drug that appears as an aerosol and is approved in Russia for the treatment of influenza. According to a new study, the drug inhibits the ability of new coronavirus to infect cells and prevent them from replicating.
Previously, doctors developed different COVID-19 treatment options, including some effective drugs. Redsivir and Desemisson are two of the best-known COVID-19 therapies, although neither drug saves lives. Redsyve can speed up the recovery of some patients, while dexamison can reduce the potentially fatal immune response in severe cases. Blood thinners can reduce clotting complications affecting almost all organs, and plasma infusion can save some lives in some cases. But none of these drugs are miracle therapy.
There is still no perfect COVID-19 cure that significantly reduces the risk of transmission — and there are no over-the-counter drugs that allow patients to treat the disease at home. Now, a team of scientists from Germany and britain believes they have found another drug that can effectively stop SARS-Cov-2 from replicating in the body.
When a new coronavirus enters the body, it infects cells. The pathogen is connected to the ACE2 subject and penetrates the cell membrane. Once inside the cell, it takes over and creates thousands of copies of itself. Host cells are killed in the process, and new SARS-CoV-2 replicas attack other cells. When this happens, the immune system takes steps to kill the pathogen and remove the infected tissue. As the viral load increases in the body, patients begin to develop symptoms, including severe symptoms. These people can also be transmitted to others. The immune system can defend against different strengths. Some people get rid of the virus faster, and their condition improves as symptoms subside. Others will deteriorate within a few days and are at risk of death.
A team of researchers in Germany and the UK used Aprotinin, a protease inhibitor that blocks viruses from entering cells. The antiviral activity of the drug will help reduce the load of SARS-CoV-2 virus and improve the COVID-19 prognosticity of patients. Scientists say the drug may work best if given early after a COVID-19 infection. Aprotinin “may be restricted in the late COVID-19 period”. At this point, it is the increase in the immune response, not the replication of the virus, that needs to be stopped.
“The main potential of antiviral drugs may lie in the early treatment of PATIENTs with COVID-19 to inhibit viral replication and thereby prevent COVID-19 from progressing into a serious, life-threatening disease.” The researchers wrote. “The use of aerosols for local Aprotinin treatment of the air and lungs, which has been clinically approved in Russia and has been reported to be very resistant to influenza patients, may have particular potential as a way to treat early COVID-19 diseases with antiviral drugs. It is worth noting that Aprotinin may also prevent the very early stages of lung damage by inhibiting the substitin metal protease, which in turn inhibits cytokine storms that eventually lead to severe, systemic COVID-19 disease. “
The researchers concluded that Aprotinin aerosols “may be a particularly promising strategy to suppress viral replication and lung damage at an early stage and prevent COVID-19 from progressing into a serious systemic disease.” However, the drug may require more clinical trials to demonstrate its efficacy with COVID-19 compared to standard care in order to be widely used to treat new coronavirus infections.
The full study was published in the journal Cell.